Safety and Tolerability of Empagliflozin (Jardiance)

1. .
Safety and Tolerability of
Empagliflozin
(Jardiance)
Anwer Ghani
FIBMS
Iraq

2. .
Empagliflozin is a sodium–glucose cotransporter (linked
transporter) 2 inhibitor: (SGLT2) inhibitor. It inhibits glucose
reabsorption in renal tubules and increase urinary glucose excretion.
The glycosuria is dose dependent.

3. .
SGLT2 demonstrated significant cardiovascular benefits making
them attractive options for the management of Type 2 diabetes
mellitus (T2DM).

4. .
The incidence of any AEs, AEs leading to treatment discontinuation,
severe AEs, and serious AEs was similar to other treatment. A study.

5. .
The empagliflozin 10/25 mg group was not associated with a higher
rate of confirmed hypoglycemia versus placebo. A study.

7. .
The incidence of events consistent with urinary tract infections
(UTI) was also similar for the empagliflozin 10/25 mg group versus
placebo (9.27 vs. 9.70/100 patient-years, respectively). Many
studies.

8. .
History of UTI was identified as a risk factor for UTI during
treatment.

9. .
Events consistent with genital infections occurred more frequently
with empagliflozin 10/25 mg than placebo (3.54 vs. 0.95/100
patient-years, respectively).

10. .
The frequency of AEs consistent with volume depletion was similar
across groups, but higher with empagliflozin 10/25 mg than placebo
in patients aged 75 years and those on loop diuretics at baseline. A
study.

11. .
Compared with DPP-4 inhibitors and GLP-1 agonists, SGLT-2
inhibitors were not associated with excess risk for severe UTIs
(defined as hospitalization for UTI, sepsis with UTI, or
pyelonephritis) or for outpatient UTIs. A very big study.

12. .
Sodium–glucose cotransporter 2 inhibitors reduce the risk of
hospitalization for heart failure in patients with heart failure (
reduced or preserved ejection fraction).